Vol. 35 No. 2 (2018): April
Antimicrobial

The challenge in colistin dosing: Updating available recommendations

PDF (Español (España))
  • Ruth Rosales,
  • Loreto Rojas,
  • Francisco Zamora,
  • Giannina Izquierdo,
  • Claudia Benavides,
  • Claudio González
Ruth Rosales
Complejo Asistencial Barros Luco Trudeau
Loreto Rojas
Hospital Puerto Montt
Francisco Zamora
Complejo Asistencial Barros Luco Trudeau
Giannina Izquierdo
Hospital Dr. Exequiel González Cortés
Claudia Benavides
Fundación Arturo López Pérez
Claudio González
Hospital Dr. Exequiel González Cortés

Published 2018-05-13

Keywords

How to Cite

1.
Rosales R, Rojas L, Zamora F, Izquierdo G, Benavides C, González C. The challenge in colistin dosing: Updating available recommendations. Rev. Chilena. Infectol. [Internet]. 2018 May 13 [cited 2025 Nov. 23];35(2). Available from: https://revinf.cl/index.php/revinf/article/view/66

Copyright (c) 2018 Ruth Rosales, Loreto Rojas, Francisco Zamora, Giannina Izquierdo, Claudia Benavides, Claudio González

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Polymyxins have been available since the 1960s, however, because of their adverse effects, their use has been reserved for the treatment of infections caused by multiresistant bacteria. The increase in the clinical experience acquired in recent years and the published medical literature have raised doubts about the information provided by the product, indicating the need to update dosage recommendations, pharmacokinetics and pharmacokinetic/ pharmacodynamic information (PK/PD). In addition, differences in concentration and dose between the different products of colistin may lead to errors of indication/administration and pose a risk to patients. In 2013, the European Medicines Agency (EMA) commissioned the Committee for Medicinal Products for Human Use (CHPM) to review available data and to make updated recommendations on the use of colistin. This procedure yielded a first report in 2014. This review highlights critical safety and efficacy aspects, reviews the recent pharmacokinetic and stability advances, the available pharmaceutical forms in Chile, providing the schemes currently recommended by health care agencies and experts in the field.
PDF (Español (España))